Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of filgotinib safety in Crohn's disease
NL-OMON54703Phase 3Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in Crohn's disease, sponsored by Galapagos NV. Primary endpoint: Safety. Started Aug 2018; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON54703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54703.